BioNTech (NASDAQ:BNTX) Earns Buy Rating from Analysts at Truist Financial

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $172.00 price objective on the stock.

A number of other analysts have also weighed in on the stock. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. HSBC boosted their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Canaccord Genuity Group increased their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Price Performance

BNTX stock opened at $122.85 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $29.45 billion, a price-to-earnings ratio of -58.50 and a beta of 0.18. The firm has a 50 day moving average price of $114.30 and a 200-day moving average price of $103.59. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same period in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts forecast that BioNTech will post -3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently modified their holdings of the business. Planning Capital Management Corp lifted its position in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. lifted its position in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in BioNTech in the 3rd quarter worth approximately $210,000. Finally, Probity Advisors Inc. bought a new stake in BioNTech during the 3rd quarter worth approximately $216,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.